Depending on numerous researches and years of experience, Creative Biolabs can provide our customers with CellRapeutics™ universal CAR (uCAR) construction service, which is an advanced and adaptable technique for CAR construction.
A diagram adapted from Shi et al., 2014.
Huan Shi, Meili Sun, Lin Liu and Zhehai Wang. Chimeric antigen receptor for adoptive immunotherapy of cancer: latest research and future prospects. Molecular Cancer 2014, 13:219.
Different from the structure of classical CAR molecule, our scientists utilize biotin or anti- Fluorescein isothiocyanate (FITC) single-chain variable fragment (scFv) as targeting region fused with a transmembrane domain (TM) and an endodomain (or two), to construct universal CAR (uCAR). This uCAR expressing T cells can recognize and eliminate cancer cells via binding FITC labeled or biotinylated antigen-specific monoclonal antibody (mAbs), and the subsequent T cell activation, proliferation, and cytokine production. Meanwhile Creative Biolabs provides various immune receptors targeting multiple and diverse antigens. The advantage of this adaptable approach for CAR construction is that it can cover almost all types of cancer and overcome the application limit of adoptive immunotherapy, allowing more flexibility in choosing target antigens.
Copyright © 2007 - 2017 Creative Biolabs. All Rights Reserved